How I treat MALT lymphoma: ‘a subjective interpretation of the gospel according to Isaacson….’

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2020) E. Zucca et al.   ANNALS OF ONCOLOGY

Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma

(2020) Alexander Grunenberg et al.   Future Oncology

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

(2019) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide plus rituximab (R 2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

(2019) Melody R. Becnel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

(2017) Chelsea C. Pinnix et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma

(2017) Barbara Kiesewetter et al.   HEMATOLOGICAL ONCOLOGY

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy

(2017) Emanuele Zucca et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

(2016) Barbara Kiesewetter et al.   BLOOD

High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial

(2015) A. J. M. Ferreri et al.   ANNALS OF ONCOLOGY

Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature

(2015) B. Kiesewetter et al.   ONCOLOGIST

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

(2014) Nathan H Fowler et al.   LANCET ONCOLOGY

Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature

(2013) B. Kiesewetter et al.   BLOOD

Efficacy of90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma

(2013) Anna Vanazzi et al.   HEMATOLOGICAL ONCOLOGY

EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT

(2011) A. Ruskone-Fourmestraux et al.   GUT